Yentreve (duloxetine hydrochloride) is now available in certain European countries, giving women suffering from moderate to severe stress urinary incontinence (SUI) a pharmaceutical treatment option for the first time. Previous treatment option
Medinox announces today the results of a preclinical study of a new drug (MX-1520) that shows a potent ansickling effect. The results were published in the June 2004 issue of The British Journ
Illinois Gov. Rod R. Blagojevich and Congressman Rahm Emanuel (D-Chicago) were joined in Chicago today by Wisconsin Governor Jim Doyle to launch the new I-SaveRx prescription drug importation program -- the first program in the nation to allow citizens
Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-
3M has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its supplemental new drug application on Aldara (imiquimod) Cream, 5% for the treatment of superficial basal cell carcinoma (sBCC), a common form of n
Pharmaceutical company, Merck Sharp & Dohme has announced an immediate voluntary world-wide withdrawal of the drug, Vioxx (rofecoxib), commonly used for patients with rheumatoid or osteoarthritis.The company's decision is based on new infor
Data presented yesterday at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR) show that the ability of teriparatide to prevent fractures remained consistent rega
A trial of beta-interferon-1a in inclusion-body myositis (IBM) has failed to find benefit from the drug in this disease. Beta-interferons counteract some of the activities of the immune
Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Ribavirin Capsules, 200 mg. Shipment of this product is
The recall of Vioxx should come as a major sign of the need to look for safer alternatives for osteoarthritis treatment, according to the Director of the Australian Centre for complementary Medicine Edu
Bush was speaking to a group of seniors at the Pueblo El Mirage RV Resort and Country Club, and urged Arizona's 780,000 Medicare beneficiaries to sign up for the new benefit in November.
According to the Department of Health and Human Services, every state except Alaska will have such an inexpensive option, along with more expensive options.
President Bush promised the group of seniors that the plan would cut their drug bills by half.
He also repeated several times that seniors did not have to change their current coverage, which has been a common concern.
Bush is encouraging seniors to be open-minded enough to listen to the options.
There are concerns that the new plan is too complicated for seniors, and the price of the Medicare drug program is thought by many to be much higher than previously anticipated, a potential $724 billion over 10 years.
Apparently what seniors get for their premiums will vary from state to state, and plan to plan, and will also depend on what drugs seniors require.
It is thought that many seniors want more information and are confused.
To date the Bush administration's drug benefit has only enticed 6 million seniors to sign up for a temporary discount card for prescription medicines, which is far fewer than was expected.
Dr. Mark McClellan, the Administrator for the Centers for Medicare and Medicaid Services has said that the average monthly premium for the prescription drug plan, which becomes active in 2006, is estimated to be $32.20, which is less than earlier estimates.
Also lower-income seniors would receive added coverage and would only have to pay a few dollars for drugs.
In an attempt to promote the Medicare drug plan, Bush has traveled to Arizona and California.